12 Deep Value Stocks to Invest In

2. Bristol-Myers Squibb Company (NYSE:BMY)

Forward P/E: 7.58

Return on Equity: 33.78%

Dividend Yield: 5.44%

Number of Hedge Fund Holders: 67

Bristol-Myers Squibb Company (NYSE:BMY) is included in our list of the 12 deep value stocks to invest in.

On November 3, 2025, BofA raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) from $50 to $52, reiterating its “Neutral” rating. The investment firm revised its 2026 revenue forecast upward 1.5% and EPS forecast upward 1% following the company’s Q3 results. Despite the company’s strong quarterly performance, BofA expects only low single-digit growth in the long term.

Meanwhile, on October 31, BMO Capital’s Evan Seigerman also maintained his “Hold” rating on Bristol-Myers Squibb Company (NYSE:BMY) with a $47 price target. The analyst cited the company’s mixed short-term outlook, marked by strong demand for Camzyos and Breyanzi offset by the slower rollout of Cobenfy. He also highlighted concerns about patent expirations and the competitive pressures they create.

The company’s October 30 earnings report preceded both of these updates, in which Bristol-Myers Squibb Company (NYSE:BMY) reported $12.2 billion in quarterly revenue, up 3%, thanks to 18% growth from its expanding Growth portfolio. The quarter also marked an increase in the company’s full-year guidance and the acquisition of Orbital Therapeutics. The acquisition reflects the company’s focus on next-generation RNA and cell therapies. The company reported GAAP EPS of $1.08.

Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical company, discovers, develops, and delivers innovative medicines that protect patients against serious diseases.